Low-Dose Edoxaban for Stroke Prevention in Elderly Patients with Atrial Fibrillation: Comment on the Edoxaban Low-Dose for Elder Care Atrial Fibrillation Patients (ELDERCARE-AF) Trial

作者
Giovanna Liuzzo,Carlo Patrono
出处
期刊:European Heart Journal [Oxford University Press]
卷期号:41 (40): 3882-3883 被引量:3
标识
DOI:10.1093/eurheartj/ehaa836
摘要

Results of the ELDERCARE-AF trial have been presented at the ESC Congress 2020 and simultaneously published in the New England Journal of Medicine (https://doi.org/10.1056/NEJMoa2012883). Key Points • ELDERCARE-AF is a company-sponsored, multicentre, double-blind trial that randomly assigned 984 very elderly Japanese patients (mean age 87 ± 4 years) with non-valvular atrial fibrillation (NVAF) and a CHADS2 score ≥2 (mean 3.1) to receive a once-daily 15-mg dose of the factor-Xa inhibitor edoxaban or placebo. Participants had poor renal function (mean creatinine clearance, 36 ± 14 mL/min), low body weight (51 ± 11.0 kg), a history of serious bleeding, continuous use of non-steroidal anti-inflammatory drugs (NSAIDs), or current use of an antiplatelet drug, all conditions that made them inappropriate candidates for direct oral anticoagulant (DOAC) therapy at doses approved for stroke prevention. • Low-dose edoxaban significantly reduced the primary efficacy endpoint, stroke, or systemic embolism, by 66% (15 vs. 44 events; 2.3% vs. 6.7% per year; P < 0.001; number needed to treat = 23). The benefit of edoxaban was largely explained by a large reduction in ischaemic stroke. There was an increase in the primary safety endpoint of major bleeding (International Society on Thrombosis and Haemostasis criteria) in the edoxaban group versus placebo (20 vs. 11 events; 3.3% vs. 1.8% per year; hazard ratio = 1.87; 95% confidence interval 0.90–3.89; P = 0.09). A non-significant P-value for such a difference reflects the inadequate statistical power of the study. The 1.5% absolute excess in major bleeding was explained by a three-fold higher number of gastrointestinal bleeding events (14 vs. 5 events; 2.3% vs. 0.8% per year). • There was no between-group difference in death from any cause (9.9% and 10.2% in the edoxaban and placebo groups, respectively). Results of the ELDERCARE-AF trial have been presented at the ESC Congress 2020 and simultaneously published in the New England Journal of Medicine (https://doi.org/10.1056/NEJMoa2012883). Direct oral anticoagulants are first-line treatment for NVAF patients to reduce the risk of stroke. However, DOACs are underused or prescribed at inappropriate doses for stroke prevention in elderly NVAF patients who face a higher risk of both ischaemic and haemorrhagic complications, because of a history of bleeding, prior falls, polypharmacy, cognitive impairment, or frailty. In the ENGAGE AF-TIMI 48 trial, only 17% of patients were ≥80 years of age and 4% were aged ≥85; the study was not specifically designed to assess the efficacy and safety of edoxaban in frail elderly patients, not eligible for standard DOAC. The 15 mg dose of edoxaban was selected based on data from the ENGAGE AF-TIMI 48 trial and a previous pharmacokinetic study in elderly Japanese patients with AF. The annualized rate of stroke or systemic embolism with the 15 mg dose of edoxaban in ELDERCARE-AF (2.3%) was similar to that of the 60 mg and 30 mg dose regimens of edoxaban (2.5% and 2.8%, respectively) in the ENGAGE AF-TIMI 48 trial among patients aged ≥80, although that study included lower-risk patients. These findings may be partly explained by the higher plasma concentration of edoxaban with severe renal insufficiency and low body weight. Can we prevent stroke in elderly NVAF patients without increasing the risk of bleeding? Not surprisingly, major bleeding was more common with edoxaban, though with a favourable balance between benefit and harm. Low-dose edoxaban did not increase the risk of intracranial haemorrhage, while it tripled the rate of gastrointestinal bleeding in a population at very high risk of these complications because of advanced age, continuous use of NSAIDs (in about one-third of patients), and antiplatelet agents (in >50%). Moreover, edoxaban caused substantially more events of bleeding defined as secondary safety endpoints. Can we generalize the ELDERCARE-AF results and translate them into daily practice? This study has important limitations: (i) the trial discontinuation rates were quite high (nearly one-third), although similar in both groups and unrelated to bleeding; (ii) median body weight was approximately 50 kg, although body mass index was 22; and (iii) the trial only involved Japanese NVAF patients and the results may not be applicable to other populations. On the other hand, ELDERCARE-AF had the merit of selecting the edoxaban dose based on previous clinical experience and a pharmacokinetic study in the target patient group. This approach should be used to define the optimal dose of other DOACs in very elderly populations. In conclusion, for very elderly patients who would not otherwise receive a DOAC, edoxaban 15 mg (when and where available) may represent an acceptable treatment option to reduce the risk of stroke, although care should be taken to avoid gastrointestinal bleeding by appropriate management of other risk factors and use of proton pump inhibitors (their use in ELDERCARE-AF was not reported). Conflict of interest: Prof. Liuzzo received grant support (to the Institution) for investigator-initiated research from American Heart Association, Italian National Health Service and Italian Minister of Education University and Research. Prof. Patrono received consultant and speaker fees from Acticor Biotech, Amgen, Bayer, GlaxoSmithKline, Tremeau, Zambon, and grant support (to the Institution) for investigator-initiated research from AIFA (Italian Drug Agency), Bayer, Cancer Research UK and European Commission; he chairs the Scientific Advisory Board of the International Aspirin Foundation.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
小蘑菇的应助被快乐的心情采纳,获得10
1秒前
等候完成签到 ,获得积分10
1秒前
李健的粉丝团团长的应助被27采纳,获得10
2秒前
Owen的应助被又又采纳,获得10
3秒前
vbmc发布了新的文献求助30
3秒前
张晓东完成签到,获得积分10
3秒前
959完成签到,获得积分10
4秒前
4秒前
5秒前
wanci的应助被tlc_191026采纳,获得10
6秒前
上官若男的应助被陈哈哈采纳,获得10
7秒前
糖醋鱼完成签到,获得积分20
7秒前
思源的应助被nhzz2023采纳,获得10
8秒前
grace发布了新的文献求助10
8秒前
田様的应助被renn采纳,获得20
8秒前
Akim的应助被执着老九采纳,获得10
9秒前
9秒前
buqi发布了新的文献求助50
10秒前
在水一方的应助被HarryChan采纳,获得10
10秒前
10秒前
zzh完成签到,获得积分10
11秒前
wh发布了新的文献求助10
12秒前
无花果的应助被我是666采纳,获得10
12秒前
莫封叶发布了新的文献求助10
13秒前
牛牛发布了新的文献求助10
14秒前
寸烛驱夜发布了新的文献求助10
14秒前
15秒前
xx发布了新的文献求助10
18秒前
buqi发布了新的文献求助50
18秒前
111完成签到,获得积分20
18秒前
ku完成签到,获得积分10
19秒前
Jaydon完成签到,获得积分10
19秒前
张寂寥完成签到 ,获得积分10
19秒前
xxx发布了新的文献求助10
20秒前
20秒前
20秒前
科研通AI65的应助被快乐的心情采纳,获得10
20秒前
elysia完成签到,获得积分20
20秒前
msuyue发布了新的文献求助10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183449
求助须知:如何正确求助?哪些是违规求助? 9572834
关于积分的说明 21827509
捐赠科研通 7780646
什么是DOI,文献DOI怎么找? 3434016
关于科研通互助平台的介绍 2558189
邀请新用户注册赠送积分活动 2480371